|
|
|
Market research forecasts growth in the animal biotech market and a public-private initiative seeks to fund new ideas in the fight against antimicrobial resistance.(698 words, 3 minutes, 29 seconds)
|
|
|
|
Market research forecasts steady growth in animal biotech |
|
|
The burgeoning animal biotech market can be expected to increase by nearly 10% per year until the end of this decade new market research finds.
Valued at $22.59 billion in 2021, the global animal biotechnology market is expected to expand at a compound annual growth rate of 9.5% through 2030, according to a report compiled by Polaris Market Research.
The animal biotech market has engendered development of “animals with enhanced growth rates” and “disease resistance,” Polaris notes. Demand for animal biotech is increasing as development of better diagnostics for diseases that affect animals enables better treatment through therapeutics and vaccines, the company adds.
Growth drivers cited in the report include demand for genetically altered therapeutic proteins that are disease resistant, the expanding role of animals in developing human pharmaceuticals, the incidence of zoonotic diseases that cross over to humans, the rise in pet ownership, advances in treatment and preventative care for pets, increased public concerns about animal welfare, and increased demand for meat and animal-based products.
Government support: “In the upcoming years, demand for animal health technology may increase as a result of the government's rising number of initiatives and programs to enhance animal health,” Polaris says. In announcing actions to back up the Biden Administration’s executive order on biomanufacturing, the USDA pledges innovations in regulation to further biotech development, as well as increased grants. The U.S. HHS Department pledges “to facilitate advancements in development of innovative animal products produced with biotechnology” including through the FDA’s Veterinary Innovation Program.
BIO has called for regulatory improvement regarding animal biotech, including through greater cooperation between the USDA and FDA.
|
|
|
|
CARB-X calls for proposals in the fight against antimicrobial resistance |
|
|
CARB-X, a public-private-initiative that aims to fill the funding gap for drugs that combat antimicrobial resistance (AMR), last week opened a call for proposals addressing vital AMR challenges.
Three areas: The call is seeking oral therapeutics, particularly those aimed at respiratory and urinary tract infections caused by Gram-positive bacteria; vaccines for neonatal sepsis; and gonorrhea products. Past calls by CARB-X have “cast a wide net,” supporting all types of AMR drugs, University of Minnesota reports, but this year CARB-X seeks maximum impact by offering funding for proposals that target areas of unmet need, as identified in a Lancet study.
Applications are being accepted from October 17 through the end of the month, with further rounds of applications opening in January and May. Further information for applicants, including a video and webinars, can be found here.
The market does a poor job of funding AMR drugs, which are most effective if used sparingly. The Boston University-based CARB-X received a commitment of $370 million in May, from HHS’s Biomedical Advanced Research and Development Authority (BARDA) and the Wellcome foundation. Since its founding in 2016, CARB-X has given $396 million in grants.
BIO member Clarametyx cited CARB-X support in last week’s announcement of FDA acceptance for a Phase 1 Study of Clarametyx’s immune-enabling biologic therapy, designed to enhance the effect of standard antibiotics.
The AMR challenge is also being taken on by the AMR Action Fund, a public-private initiative that includes many BIO members and seeks to get two to four new antibiotics to patients by 2030.
Ultimately, we need legislation, like measures supported by BIO in the war against AMR. |
|
|
More Health Care News
New York Times: Doctors start to find hope for cancer vaccines
“Unlike vaccines for infectious diseases, the promise of cancer vaccines has only dangled in front of researchers, despite their arduous efforts. Now, though, many hope that some success may be nearing in the quest to immunize people against cancer.” |
|
|
|
|
|
President Biden’s Wednesday: Traveling to Vail, CO, to speak about “America’s iconic outdoor spaces” before heading to Southern California to discuss infrastructure investments in Brentwood, CA, according to reports.
What’s Happening on Capitol Hill: The Senate Judiciary Committee will hold hearings on nominations of several judges. The House is in recess. |
|
|
|
|
